Balkrishna Acharya, Sakat Sachin Shridhar, Joshi Kheemraj, Paudel Sandeep, Joshi Deepika, Joshi Kamal, Ranjan Ravikant, Gupta Abhishek, Bhattacharya Kunal, Varshney Anurag
Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, India.
University of Patanjali, Patanjali Yog Peeth, Haridwar, India.
Front Pharmacol. 2019 Jul 1;10:659. doi: 10.3389/fphar.2019.00659. eCollection 2019.
Rheumatoid arthritis (RA) is defined as a chronic autoimmune inflammatory disorder that causes damage to limb joints and progressive injuries to secondary organs. Medical practitioners prescribe Methotrexate (MTX) as standard care medicine for treating RA. However, the long-term application of MTX has shown to have adverse health-related effects. Divya Amvatari Ras (DAR), an Indian Ayurvedic herbo-mineral formulation, has been described in ancient texts to provide relief from RA inflammation associated distress. Therefore, in the present study, we explored the biocompatibility, anti-inflammatory, and anti-arthritic efficacy of DAR using and disease models. Using carrageenan (CA)-stimulated Wistar rat paw edema model, we showed a reduction in inflammation-induced paw edema at human equivalent dose of DAR. Anti-rheumatic efficacy of DAR was studied using collagen-antibody cocktail (C-Ab) Induced Arthritis (CAIA) mouse model. The onset of RA in the CAIA mice was determined using parameters such as the increase in arthritis score, and induction of disease associated lesions in the ankle and knee joints, and increase in mechanical and thermal hyperalgesia. Treatment of CAIA animals with a human equivalent dose of DAR significantly reversed the RA-associated pathogenesis. These effects were comparable with the standard of care RA drug, MTX. DAR acted at multiple levels of inflammation associated with RA to reduce progressive pathogenesis. Animal serum biochemistry showed DAR was capable of ameliorating RA induced increase in liver enzyme Alanine Aminotransferase (ALT) and pro-inflammatory cytokine interleukin 6 (IL-6). In the lipopolysaccharide stimulated THP-1 cells, DAR was found to inhibit the release of IL-6, IL-1β, TNF-α, and upstream inflammatory gene regulatory protein, NFκB. The study endorsed the anti-arthritic and anti-inflammatory activity of the Indian Traditional herbo-mineral medicine, DAR. These results also confirm that DAR was highly biocompatible and would show minimal health-related side effects than those associated with standard of care MTX. Taken together, we show that the DAR could be utilized as a promising alternative or complementary therapy for treating rheumatoid arthritis.
类风湿性关节炎(RA)被定义为一种慢性自身免疫性炎症性疾病,会导致肢体关节损伤和继发器官的进行性损伤。医生将甲氨蝶呤(MTX)作为治疗RA的标准护理药物。然而,长期应用MTX已显示出对健康有不良影响。Divya Amvatari Ras(DAR)是一种印度阿育吠陀草药 - 矿物质配方,在古代文献中已有记载,可缓解与RA炎症相关的痛苦。因此,在本研究中,我们使用疾病模型探索了DAR的生物相容性、抗炎和抗关节炎功效。使用角叉菜胶(CA)刺激的Wistar大鼠爪肿胀模型,我们发现在DAR的人等效剂量下,炎症诱导的爪肿胀有所减轻。使用胶原蛋白 - 抗体混合物(C - Ab)诱导的关节炎(CAIA)小鼠模型研究了DAR的抗风湿功效。使用诸如关节炎评分增加、踝关节和膝关节疾病相关病变的诱导以及机械性和热痛觉过敏增加等参数来确定CAIA小鼠中RA的发病情况。用人等效剂量的DAR治疗CAIA动物可显著逆转与RA相关的发病机制。这些效果与RA护理标准药物MTX相当。DAR在与RA相关的多个炎症水平上起作用,以减少进行性发病机制。动物血清生化显示DAR能够改善RA诱导的肝酶丙氨酸氨基转移酶(ALT)和促炎细胞因子白细胞介素6(IL - 6)的增加。在脂多糖刺激的THP - 1细胞中,发现DAR可抑制IL - 6、IL - 1β、TNF - α以及上游炎症基因调节蛋白NFκB的释放。该研究认可了印度传统草药 - 矿物质药物DAR的抗关节炎和抗炎活性。这些结果还证实DAR具有高度生物相容性,并且与护理标准MTX相比,显示出与健康相关的副作用最小。综上所述,我们表明DAR可作为治疗类风湿性关节炎的有前景的替代或补充疗法。